Navigation Links
Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant

FRANKLIN, Mass., Aug. 27, 2015 /PRNewswire/ -- A recent study by Feucht et al, published in the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, which is based on an "inlay" Arthroplasty design, versus an "onlay" design implant for isolated patellofemoral disease. While both implant groups showed similar improvements in function and pain scores, none of the patients in the "inlay" group showed progression of osteoarthritis (OA). However, 53% of the patients in the "onlay" group, showed progression of OA in other parts of the knee, namely the femoral-tibial compartments. Progression of OA is the number one reason for revising a patellofemoral implant to a Total Knee.

Steven Ek, President and CEO of Arthrosurface® commented, "Over 20 years ago, the orthopedic community largely abandoned patellofemoral joint arthroplasty. A relatively high number of these first generation implants, which were simply mounted on top of the existing arthritic joint surfaces, were revised early to total knees due to the progression of OA. In 2006, after reviewing the clinical history of PF arthroplasty, Arthrosurface® took a completely different approach in the design of its PF implants.  They were specifically created to be recessed and set into the arthritic joint surface, preserving the native biomechanics of the knee and replicating the patient's existing joint surface. This novel concept became known as an "inlay" implant. I believe our patient's remarkable success stories and their unmatched return to high-demand activities reignited interest in treating isolated PFJ disease within the orthopedic community.  Many of the large orthopedic companies have since re-introduced an updated version of their PF devices, but they are all still "onlay" designs. I truly believe that they have missed the point. This publication identifies the profound clinical outcome differences in tibiofemoral OA progression between "onlay" and "inlay" devices. We are very happy that this study has validated our design team's insight. Our hope is that younger surgeons who have begun treating patients using PF implants will fully appreciate the clinical history of PF arthroplasty devices in the context of this study."

While it is not known why over half of the patients with the "onlay" devices developed progressive OA in the other knee compartments, the authors of the study stated that, "one hypothesis is that the more anatomic approach of the inlay design better reproduces the complex kinematics of the patella-femoral joint. Soft tissue irritation due to over-stuffing of the patella-femoral joint with an "onlay" component may cause persistent synovitis, which is a well-known risk factor for the development and progression of OA due to secretion of pro-inflammatory cytokines."

Matthias Schurhoff MD, VP of Clinical Affairs at Arthrosurface, commented, "Historically, problems related to poor implant design are seen early on, usually within the first few years after implantation. This study highlights a concern that 'onlay' implants for isolated PF disease may disturb normal knee kinematics leading to overloading and disease progression in other parts of the joint. 'Inlay' arthroplasty may offer younger patients a better long term option, especially if they want to continue to stay active."

About Arthrosurface
Arthrosurface, Inc. is a leader in the design and distribution of orthopedic devices for joint preservation, restoration and resurfacing. The HemiCAP® system is a unique, less invasive technology that can be used to treat a wide variety of joint conditions caused by trauma, injury and disease. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world.


Logo -

SOURCE Arthrosurface, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
(Date:9/1/2020)... ... 2020 , ... Breast and ovarian cancers are common diseases that affect many ... cancers (about 7,500 women per year) and 10% of ovarian cancers (about 2,000 women ... genes are detectable in the Women’s Excellence Genetic Testing Program. , Dr. Jonathan Zaidan, ...
(Date:8/31/2020)... ... August 31, 2020 , ... If you live in New York City you will always ... makes sense, it’s the law of supply and demand, but are plastic surgeons in New ... significant percentage of their patients that make the four-hour trip to have expert aesthetic treatments ...
(Date:8/28/2020)... ... August 28, 2020 , ... Cano Health, LLC, a leading ... and San Antonio is happy to announce that it has selected Tejano musician ... capacity he will serve as community advisor, advertising talent, and creative consultant for ...
Breaking Medicine Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... BluePearl Specialty and Emergency ... Prevention’s (AFSP) annual signature event, Out of the Darkness (OOTD), which unites more ... raise awareness of suicide prevention. To ensure Associate safety, BluePearl will not be ...
(Date:9/2/2020)... WASHINGTON, Pa. (PRWEB) , ... September 02, 2020 ... ... development of enterprise software for healthcare payers administering Medicare Advantage and Special Needs ... Duals Online presented by America’s Health Insurance Plans (AHIP). RAM is supporting the ...
(Date:9/1/2020)... Fla. (PRWEB) , ... September 01, 2020 , ... ... Reconstructive Surgeon with specialty fellowship training in aesthetic surgery of the face, breast, ... MD – the only female-owned premier boutique plastic surgery and aesthetic practice in ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, ... Palsy Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign ... fully virtual challenge, STEPtember meets everyone wherever they are at this moment — encouraging ...
(Date:8/31/2020)... ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis ... planet are in a state of panic, experiencing deep anxiety, immense stress, and right now ... solution is timely when most people on the planet are experiencing a great degree of ...
Breaking Medicine News(10 mins):